Eli Lilly stock skidded early Friday as Novo Nordisk's oral Wegovy continued to outpace Lilly's new obesity pill, Foundayo.
You are being redirected to the original discussion. Please continue if you want to read the full post.
Continue to original articleYou will be redirected in 3 seconds.